Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial

Kari L Kendra¹, Shay L Bellasea^{2

3}, Zeynep Eroglu⁴, Siwen Hu-Lieskovan⁵, Katie M Campbell⁶, William E Carson 3rd⁷, David A Wada⁵, Jose A Plaza⁷, Jeffrey A Sosman⁸, Gino K In⁹, Alexandra Ikeguchi^{10

11}, John Hyngstrom^{5

12}, Andrew S Brohl⁴, Nikhil I Khushalani⁴, Joseph Markowitz⁴, George Negrea¹³, Samer Kasbari¹⁴, Gary C Doolittle¹⁵, Umang Swami⁵, Toni Roberts¹⁶, Boban N Mathew¹⁷, Egmidio Medina⁶, Ignacio Baselga-Carretero⁶, Cynthia R Gonzalez⁶, Ivan Perez Garcilazo⁶, Agustin Vega-Crespo⁶, Jia Ming Chen⁶, Nataly Naser Al-Deen⁶, Sapna P Patel¹¹, Elad Sharon^{18

19}, James Moon^{2

3}, Michael C Wu^{2

3}, Antoni Ribas²⁰

Affiliations

¹ Ohio State University Wexner Medical Center, Columbus, OH, USA. kari.kendra@osumc.edu.
² SWOG Statistics and Data Management Center, Seattle, WA, USA.
³ Fred Hutchinson Cancer Center, Seattle, WA, USA.
⁴ H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
⁵ Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
⁶ Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
⁷ Ohio State University Wexner Medical Center, Columbus, OH, USA.
⁸ Northwestern University, Chicago, IL, USA.
⁹ Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
¹⁰ University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA.
¹¹ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹² RUSH MD Anderson Cancer Center, Chicago, IL, USA.
¹³ Lewis Cancer and Research Pavilion, Savannah, GA, USA.
¹⁴ Southeastern Medical Oncology Center, Goldsboro, NC, USA.
¹⁵ University of Kansas Cancer Center, Westwood, KS, USA.
¹⁶ Saint Michael Cancer Center, Bremerton, WA, USA.
¹⁷ Masonic Cancer Alliance, Freeman Cancer Center, Pittsburgh, PA, USA.
¹⁸ Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
¹⁹ Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
²⁰ Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.

PMID: 40858972
DOI: 10.1038/s41591-025-03975-2

Published Erratum

Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial

Kari L Kendra et al. Nat Med. 2025.

. 2025 Aug 26.

doi: 10.1038/s41591-025-03975-2. Online ahead of print.

Authors

Affiliations

¹ Ohio State University Wexner Medical Center, Columbus, OH, USA. kari.kendra@osumc.edu.
² SWOG Statistics and Data Management Center, Seattle, WA, USA.
³ Fred Hutchinson Cancer Center, Seattle, WA, USA.
⁴ H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
⁵ Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
⁶ Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
⁷ Ohio State University Wexner Medical Center, Columbus, OH, USA.
⁸ Northwestern University, Chicago, IL, USA.
⁹ Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
¹⁰ University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA.
¹¹ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹² RUSH MD Anderson Cancer Center, Chicago, IL, USA.
¹³ Lewis Cancer and Research Pavilion, Savannah, GA, USA.
¹⁴ Southeastern Medical Oncology Center, Goldsboro, NC, USA.
¹⁵ University of Kansas Cancer Center, Westwood, KS, USA.
¹⁶ Saint Michael Cancer Center, Bremerton, WA, USA.
¹⁷ Masonic Cancer Alliance, Freeman Cancer Center, Pittsburgh, PA, USA.
¹⁸ Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
¹⁹ Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
²⁰ Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.

PMID: 40858972
DOI: 10.1038/s41591-025-03975-2

No abstract available

PubMed Disclaimer

Erratum for

Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Kendra KL, et al. Nat Med. 2025 Aug 14:10.1038/s41591-025-03875-5. doi: 10.1038/s41591-025-03875-5. Online ahead of print. Nat Med. 2025. PMID: 40813711 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial

Affiliations

Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources